Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;63(7):700-708.
doi: 10.1007/s00108-022-01372-2. Epub 2022 Jun 27.

[Targeted treatment of non-small cell lung cancer]

[Article in German]
Matthias Scheffler  1 , Sebastian Michels  2 , Lucia Nogova  2
Affiliations
Review

[Targeted treatment of non-small cell lung cancer]

[Article in German]
Matthias Scheffler et al. Inn Med (Heidelb). 2022 Jul.

Abstract
in English, German

Non-small cell lung cancer (NSCLC) has made a remarkable development in recent decades with respect to its perception. In the late 1990s it was the "problem child" as the main cause of cancer with increasing tendencies, especially in women and with a pronounced stigmatization. It is now the role model as a biologically rational targeted treatment based on molecular dependencies of the tumor with a vast improvement of the traditionally poor survival times. Molecular tumor boards have long followed the NSCLC example in the assessment of targeted treatment approaches for other tumor entities. This review article gives an overview of the current possibilities for targeted treatment of NSCLC, which nowadays are applicable for nearly one third of all patients with NSCLC.

Das nichtkleinzellige Lungenkarzinom („non-small cell lung cancer“ [NSCLC]) hat in den vergangenen Dekaden eine beachtliche Entwicklung hinsichtlich seiner Wahrnehmung genommen: Vom „Sorgenkind“ als Hauptkrebstodesursache mit steigenden Inzidenzen vor allem bei Frauen in den späten 1990er-Jahren und ausgeprägter Stigmatisierung hin zum Leitbild biologisch rationaler, zielgerichteter Therapie auf Basis molekularer Abhängigkeiten des Tumors mit einer Vervielfachung der traditionell schlechten Überlebenszeiten. Längst folgen molekulare Tumorboards dem NSCLC-Beispiel bei der Beurteilung zielgerichteter Therapieansätze für andere Tumorentitäten. In dieser Übersichtsarbeit möchten wir einen Überblick über aktuelle Möglichkeiten der zielgerichteten Therapie des NSCLC geben, die mittlerweile bereits für fast ein Drittel aller Patienten mit NSCLC infrage kommen.

Keywords: Drug resistance, neoplasm; Molecular genetic analysis; Mutation/BRAF; Mutation/EGFR; Mutation/KRAS.

PubMed Disclaimer

References

Literatur

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA A Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708 - DOI
    1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98. https://doi.org/10.1056/NEJMoa011954 - DOI - PubMed
    1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY‑S, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005 - DOI - PubMed
    1. Paz-Ares L, Ciuleanu T‑E, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet P‑J, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198–211. https://doi.org/10.1016/S1470-2045(20)30641-0 - DOI - PubMed
    1. Mok TS, Wu Y‑L, Thongprasert S, Yang C‑H, Chu D‑T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J‑J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957. https://doi.org/10.1056/NEJMoa0810699 - DOI - PubMed